הזדמנות עסקית | קוריאה | 99630 | שיתוף פעולה | כימיה, רפואה ופרמצבטיקה | 29/05/2019

Quinone-based small molecules as a novel therapy for Alzheimer's disease and Amyloidosis

הזדמנות עסקית זאת היא בת למעלה מחצי שנה מומלץ לבדוק האם היא עדיין בתוקף

No.1 domestic company with the highest yield in the field of neuropsychology.

There are approximately 80 types of medicines are produced including neuro-psychology therapy, such as treatment of Schizophrenia, tranquilizer, antidepressant, anti-epileptic drugs, and treatment for alcoholic disease.

Function
- Technology enables to make small molecules based on Quinone effective beta coagulation inhibitor
- Two novel compositions that show suppressant of fibrosis and a beta aggregation in vitro
- Ease symptoms of Alzheimer in vitro
- Dynamic research for drugs and bio-availability proves stability (P.O & I.P.)
- Research for toxicity -> Not found

Benefit
- Novel therapy for Alzheimer’s disease
- The technology is anticipated to be applicable on Parkinson disease and type 2 Diabetes.

The company is interested in:

Industry-academic cooperation
License

 

פרטים על ההזדמנות

קוריאה
  • Country:
    Korea
  • Number:
    99630
  • Activity:
    Joint Ventures
  • Branch:
    Chemistry, Medicine, Pharmaceuticals and Cosmetics
  • Published:
    29/05/2019
Member of trade organization, association or chamber of commerce :
Change the CAPTCHA code

חדשות חמות